Lysosome Proteasome Inhibitors
Lysosome Proteasome Inhibitors - Related Videos
02:18
The Proteasome
0 Views •
2020
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner. In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:13
The Proteasome
0 Views •
2023
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner. In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
04:12
Protein Aggregate Formation Assay: A Method to Detect and Quantify Protein Aggregation in Cultured Cells upon Induction by Proteasome Inhibitor
0 Views •
2025
In this video, we demonstrate a cell-based protein aggregation assay using proteasome inhibitors, which block proteasome activity, preventing misfolded, mutant proteins, fused to a fluorescent label, from undergoing ubiquitin-dependent proteasomal degradation, leading to their accumulation within the cell cytoplasm. The protein aggregates are then visualized and quantified by fluorescence microscopy.
07:43
Assaying Proteasomal Degradation in a Cell-free System in Plants
0 Views •
Cited by 26 •
2014
Targeted protein degradation represents a major regulatory mechanism for cell function. It occurs via a conserved ubiquitin-proteasome pathway, which attaches polyubiquitin chains to the target protein that then serve as molecular “tags” for the 26S proteasome. Here, we describe a simple and reliable cell-free assay for proteasomal degradation of proteins.
09:57
Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach
0 Views •
Cited by 1 •
2016
This protocol uses both subunit coexpression and postlysis subunit mixing for a more thorough examination of recombinant proteasome assembly.
FAQs
Researchers can compare the effects of lysosome-directed and proteasome-directed compounds to determine which protein-clearance route contributes to a cellular response. Blocking one system selectively reveals proteins or processes that depend more heavily on the other, while changes after combined inhibition indicate overlapping or compensatory activity. This comparison is useful for analyzing autophagy, ubiquitin-dependent turnover, and intracellular protein balance.
These interventions disrupt lysosomal degradation through different mechanisms. Preventing acidification interferes with the environment required for lysosomal function, whereas inhibiting hydrolytic enzymes directly reduces the breakdown of proteins within the compartment. Distinguishing the two helps researchers determine whether an observed effect reflects altered lysosomal conditions, reduced enzymatic activity, or both, improving interpretation of protein-accumulation experiments.
Proteasome inhibitors block catalytic activities responsible for processing proteins targeted for degradation, including many ubiquitin-marked substrates. As turnover slows, short-lived or damaged proteins accumulate and can disturb cellular protein balance. Measuring these changes allows investigators to examine how the ubiquitin-proteasome pathway contributes to protein quality control and to identify cellular responses triggered by proteotoxic stress.
The two systems provide complementary routes for removing unwanted proteins. When both are impaired, cells have fewer opportunities to clear damaged or short-lived proteins, so accumulation becomes more pronounced. This burden can impair cellular function and intensify stress responses. At sufficiently strong levels of inhibition, the resulting proteotoxic stress may promote cell death, making combined treatment useful for studying system dependence.
A typical study compares untreated cells with groups exposed to a lysosome-directed compound, a proteasome inhibitor, or both. Investigators then assess protein accumulation, cellular function, and stress-related responses under the selected conditions. Including separate treatments helps attribute outcomes to a particular degradation system, while the combined condition tests whether the pathways compensate for one another.
They are useful when researchers need to determine how cells remove proteins through lysosomal versus proteasomal routes. Selective disruption can reveal pathway contributions, dependence, and compensatory responses during proteotoxic stress. In biology studies, these compounds support analysis of autophagy, ubiquitin-dependent degradation, and the consequences of impaired protein clearance without treating all intracellular turnover as a single process.
Tumor cells may depend strongly on protein quality-control mechanisms to manage the burden of abnormal or damaged proteins. Inhibiting lysosomal or proteasomal degradation provides a way to test whether disrupting that dependence causes greater stress or cell death in experimental models. Such studies evaluate potential strategies for targeting tumor cells while clarifying which degradation pathway supports their survival.